The aim of this study was to analyze KRAS and NRAS mutational status in both lesions of SP-CRC patients as well as the metastatic tissue and determine the necessity of testing for both lesions in order to provide more precise information for supporting clinical decision. This evidence concerns the gene KRAS and colorectal carcinoma.